Hypertension: LCZ696, a novel dual inhibitor of neprilysin and the angiotensin II receptor, shows promise in phase II trial

被引：2
作者：
Lucchese B.
机构：
来源：
Nature Reviews Nephrology | 2010年 / 6卷 / 7期
关键词：
D O I：
10.1038/nrneph.2010.72
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：383 / 383
相关论文
共 50 条
[21]   Sacubitril-Valsartan (LCZ696) in the Treatment of Systemic Hypertension: An Updated Review of Neprilysin Inhibition Combined with Angiotensin II Receptor Blockade [J].
Katz, Miriam E. ;
Frishman, William H. ;
Aronow, Wilbert S. .
CARDIOLOGY IN REVIEW, 2025, 33 (05) :437-440
[22]   LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone [J].
Kusaka, Hiroaki ;
Sueta, Daisuke ;
Koibuchi, Nobutaka ;
Hasegawa, Yu ;
Nakagawa, Takashi ;
Lin, BoWen ;
Ogawa, Hisao ;
Kim-Mitsuyama, Shokei .
AMERICAN JOURNAL OF HYPERTENSION, 2015, 28 (12) :1409-1417
[23]   Treatment with LCZ696, an Orally Active Angiotensin Receptor Neprilysin Inhibitor Prevents Ischemic Brain Damage [J].
Bai, Hui-Yu ;
Mogi, Masaki ;
Nakaoka, Hirotomo ;
Kan-no, Harumi ;
Tsukuda, Kana ;
Chisaka, Toshiyuki ;
Wang, Xiao-Li ;
Kukida, Masayoshi ;
Shan, Bao-Shuai ;
Iwanami, Jun ;
Horiuchi, Masatsugu .
HYPERTENSION, 2014, 64
[24]   LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure [J].
Martin P Lefkowitz .
BMC Pharmacology and Toxicology, 16 (Suppl 1)
[25]   Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction [J].
Sadayoshi Ito ;
Minoru Satoh ;
Yuko Tamaki ;
Hiromi Gotou ;
Alan Charney ;
Naoko Okino ;
Mizuki Akahori ;
Jack Zhang .
Hypertension Research, 2015, 38 :269-275
[26]   Safety profile of novel angiotensin II type-1 receptor neprilysin inhibitor lcz696 (sacubitril/valsartan) - a collaborative summary from clinical trials [J].
Barano, A. Z. ;
Putri, E. N. ;
Addai, M. F. ;
Abduh, M. ;
Ilmasari, D. .
EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 :586-587
[27]   LCZ696, a First-in-Class Angiotensin Receptor-Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension [J].
Kario, Kazuomi ;
Tamaki, Yuko ;
Okino, Naoko ;
Gotou, Hiromi ;
Zhu, Min ;
Zhang, Jack .
JOURNAL OF CLINICAL HYPERTENSION, 2016, 18 (04) :308-314
[28]   Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction [J].
Ito, Sadayoshi ;
Satoh, Minoru ;
Tamaki, Yuko ;
Gotou, Hiromi ;
Charney, Alan ;
Okino, Naoko ;
Akahori, Mizuki ;
Zhang, Jack .
HYPERTENSION RESEARCH, 2015, 38 (04) :269-275
[29]   Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction [J].
Voors, Adriaan A. ;
Gori, Mauro ;
Liu, Licette C. Y. ;
Claggett, Brian ;
Zile, Michael R. ;
Pieske, Burkert ;
McMurray, John J. V. ;
Packer, Milton ;
Shi, Victor ;
Lefkowitz, Martin P. ;
Solomon, Scott D. .
EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 (05) :510-517
[30]   Renal protective effects and mechanisms of the angiotensin receptor-neprilysin inhibitor LCZ696 in mice with cardiorenal syndrome [J].
Li, Ying ;
Kang, Li ;
Rong, Kai ;
Zhang, Yue ;
Suo, Ya ;
Yuan, Meng ;
Bao, Qiankun ;
Shao, Shuai ;
Tse, Gary ;
Li, Rong ;
Liu, Tong ;
Li, Guangping .
LIFE SCIENCES, 2021, 280
12345